News & Events about Zentalis Pharmaceuticals Inc.
Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for treatment with azenosertib Company also announces collaborations with Foundation Medicine and Roche ...
Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types including platinum-resistant ovarian cancer Company anticipates sharing clinical data from ovarian chemotherapy combination study, including data on CCNE1 amplification and / or Cyclin E1 expression, in the first...
Business Wire
4 months ago
Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) (Zentalis or the Company). The investigations concern whether certain of the Zentalis officers and directors breached their fiduciary duties to...
Globe Newswire
5 months ago
NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) breached their fiduciary duties to shareholders. The investigation concerns potential ...
Zentalis Pharmaceuticals (NASDAQ:ZNTL Get Rating) had its price target reduced by Wells Fargo & Company from $52.00 to $46.00 in a research note released on Monday, The Fly reports. A number of other research firms have also weighed in on ZNTL. HC Wainwright reduced their price objective on shares ...